📽️ Now on-demand 👉 Check out @natera.com's #ISHLT2026 industry symposium to learn more about how donor-derived cell-free DNA not only rules out rejection with high confidence but also detects broader allograft injury. 💡🫁 🔗 bit.ly/4oBNXck #ddcfDNA #LungTransplantation #MedSky #TransplantSky

At #ATC2026Boston, Natera and our collaborators will share 21 presentations, including seven oral presentations. We're excited to be part of the conversations happening at ATC in Boston. If you're attending, we'd love to connect! Stop by booth #412 to meet our team. https://ow.ly/csob50ZemSc

Cancer survivorship looks different for everyone. And we all know someone living it - they’re our colleagues, neighbors, friends, and family. Talking about it is powerful. If you or someone you know is navigating life after a cancer diagnosis, you're not alone. ow.ly/v7hZ50Z8vEk #CancerSurvivorsDay

Through our collaboration with CytoDyn, Signatera™ will be used to evaluate molecular response patterns associated with leronlimab treatment in metastatic colorectal cancer. Read more in our press release: https://ow.ly/8Wgn50Z7E8T

We’ve teamed up with our partner, Diakonos, advancing our shared commitment to improve outcomes for patients with advanced melanoma. https://ow.ly/2mMb50Z5Hcg

Heading into ASCO, we’re sharing our announcement of a new innovative breast cancer trial sponsored by Natera, called SIGNAL-ER 101. https://ow.ly/sRGl50Z5muB

We're excited to announce the upcoming launch of a major enhancement to our Panorama™ NIPT. Read about it in our press release: https://ow.ly/LM7A50Z4IBE

We are proud to share that the FDA has approved Signatera™ CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq®) in muscle-invasive bladder cancer. This is the first FDA-approved molecular residual disease (MRD) companion diagnostic. Read more: www.natera.com/company/news...

Mother’s Day honors the courage, compassion, and steadfastness of mothers and mother figures. We celebrate the hopeful news and quiet milestones that define the path to motherhood. We also recognize this day holds unique meaning for everyone: those celebrating, those hoping, and those remembering.💙💚

Yesterday we announced financial results for Q1 2026. We delivered strong performance across all areas of focus, capping an exciting period of growth for Natera. Most importantly, we continue to remain confident in our ability to continue transforming care for our patients. https://ow.ly/pFrb50YWG9v

Thank you for an incredible #ISHLT2026! With 17 abstracts, including six oral presentations, we showcased the clinical utility of Prospera™ in heart and lung transplantation. https://ow.ly/ky5B50YRjTe Looking forward to next year! International Society for Heart and Lung Transplantation (ISHLT)

Join our upcoming webinar, Advancing testicular cancer management with ctDNA: Clinical utility of Signatera™ for MRD detection and surveillance. Register here: https://ow.ly/hEGu50YQLGW

Join our upcoming webinar: https://ow.ly/UVti50YNCFS Hear from Ronen Schneider, Medical Director of Renal Genetics and moderator Dinah Clark, Director of Medical Education for Natera on real-world evidence from RenasightIQ™.

Thank you everyone at #ISHLT2026 who attended our lung symposium, featuring Jason Li, Transplant Fellow, Fatima Anjum, MD, MHA, Nirmal S. Sharma, MD, and Holly Keyt, MD. #Natera International Society for Heart and Lung Transplantation (ISHLT)

TODAY: Don't miss our presentations at #ISHLT2026, including one featuring data from the TRIFECTA-Heart study and another highlighting the use of dd-cfDNA in lung transplantation. https://ow.ly/3jpR50YPavO International Society for Heart and Lung Transplantation (ISHLT)

Brent Lampert, DO, presented the poster, dd-cfDNA Informs Clinical Decision-Making in Heart Transplantation: Insights from the ProTECT Study, at #ISHLT2026. Learn more: https://ow.ly/IIax50YP2U1 #Natera International Society for Heart and Lung Transplantation (ISHLT)

A broad body of evidence supporting our Prospera™ test will be presented at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting this week. https://ow.ly/zMIG50YO92h #ISHLT2026 #Natera International Society for Heart and Lung Transplantation (ISHLT)

In support of National Infertility Awareness Week, we're proud to partner with organizations like RESOLVE, which provides resources and support for people on their family planning journey. #NIAW2026 Learn more: https://ow.ly/J2Lx50YNA0H

🚀 Our lab teams truly go "To Infinity and Beyond for Our Patients." While our technology provides the platform, it is the care and expertise of our teams that transform every sample into a meaningful answer. #MedicalLaboratoryProfessionalsWeek #LabWeek

Members of our team attended the inaugural Becker's Healthcare Oncology Summit in Chicago this week. As a gold sponsor, Natera joined leading oncology executives and providers from across the country to discuss the latest trends shaping health system oncology service lines.

Join us at Becker's Oncology Executive Summit and don't miss the Precision Oncology panel featuring Minetta Liu, Oncology and Early Cancer Detection, Natera. #MRD #ctDNA #Natera #BeckersAnnualMeeting Learn more: https://ow.ly/53V650YIkOi#MRD

Natera will present 20 abstracts, including two oral presentations, at the 2026 American Association for Cancer Research® (AACR) Annual Meeting, April 17-22. We look forward to sharing these presentations alongside our academic and clinical collaborators at #AACR26. https://ow.ly/yNn050YF3LO

Dr. Lodhi shares how she can remain proactive for her potentially high risk transplant patients with routine use of the Prospera™ test. Learn more: https://ow.ly/KRl050YCW69 #Natera #Transplant

Don't miss our upcoming webinar featuring an expert panel highlighting ultrasensitive #MRD with phased variants. #ctDNA Register here 👉 https://ow.ly/4ntt50YCTae

A new prospective study in Clinical Cancer Research highlights how Signatera™ was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery. https://ow.ly/CPuK50YBV7Z

Proud to support the National Kidney Foundation at the 43rd Annual Great Chefs of the West. Our team joined an inspiring event dedicated to advancing research, expanding patient support and increasing education for those affected by kidney disease. https://ow.ly/Ol6h50YwY0X

Minetta Liu, MD, chief medical officer for Natera oncology, recently participated in discussions about the importance of molecular residual disease testing and the role of circulating tumor DNA. Learn more about Signatera™ during an upcoming webinar: https://ow.ly/z4fA50Yvrhv #PMWC26 #Natera #ctDNA

Join Gerald Feldman, MD, PhD and Brian Schoenfeld, MS, LCGC, in our upcoming webinar as they provide an overview of the importance of genomic testing for patients with potential rare disease and introduce you to the new Zenith™ platform from #Natera. Register today: https://ow.ly/JOZl50YuWNB

Two new publications highlight the clinical utility of Signatera™ in anal and rectal cancers. By providing earlier insight into molecular residual disease, Signatera can support more individualized surveillance and treatment decisions. https://ow.ly/zVCZ50YuTC5 #ctDNA #Natera

Register today for our upcoming webinar with Fenting Yan, MD, PhD and Jamie McKenzie, MD highlighting three of the twelve studies presented at the San Antonio Breast Cancer Symposium (SABCS). Reserve your spot: https://ow.ly/tLe450YtAIR #Natera #ctDNA

Up to 1 in 5 people w/ chronic kidney disease (CKD) may have a genetic cause, & w/out genetic testing, those insights stay hidden. Identifying the underlying cause of CKD can help improve outcomes. Learn how genetic testing can support kidney health: https://ow.ly/mW9e50YsQYB #WorldKidneyDay

Join Krzysztof Misiukiewicz, MD and Michael Krainock, MD, PhD on a live webinar as they review and discuss the latest clinical data supporting the use of Signatera™ #ctDNA molecular residual disease (MRD) testing to support HNSCC patient care. Register here: https://ow.ly/ftph50YsAmW

Reserve your spot today for our upcoming webinar, From ASCO GU to real-world practice: Personalized tumor-informed ctDNA in bladder cancer management. 🧬Learn how leading clinicians are using #ctDNA to guide management decisions. Register here: https://ow.ly/uTHs50Ys3hu#ctDNA@vadimkoshkin.bsky.social

Don’t miss our upcoming event, Shaping the future of skin cancer: Tumor-informed ctDNA-guided intervention. Register here: https://ow.ly/tPbL50YrR6N #ctDNA #Natera

Here’s a snapshot from last week, when #Natera was recognized as Healthcare Technology Company of the Year! Oded Wohl, our Vice President of Product Development and Engineering, accepted on behalf of our team and spoke about our mission. Thank you to Healthcare Technology Report for this honor.

Thank you to everyone who stopped by our booth during #CEoT2025 to speak with our team. A big thank you to symposium speakers Sanjeev Akkina, MD and Maen Abdelrahim, MD, PhD, BPharm, who presented on the intersection of oncology and transplantation.

Colorectal cancer remains one of the most common cancers worldwide. Wearing blue is one way to show support, start conversations and encourage screening. Together, we can help increase awareness and promote access to the tools that make early detection possible. 💙 #DressInBlueDay #CRCMonth #Natera

Amanda was diagnosed with stage IV CRC at 36 while pregnant. Now in survivorship, she uses Signatera™ for post-op surveillance to help manage recurrence risk. With CRC rising in people under 50, earlier detection and informed care matter more than ever. https://ow.ly/hmhE50Ypeuw #Natera #CRCMonth

More than 7,000 rare diseases have been identified worldwide. While each condition affects a relatively small population, together they impact over 350 million people globally. The majority are genetic, often chronic and serious, and many begin in childhood.

This is an important day for Natera with the announcement of new evidence that will be shared on Signatera™ at ASCO GU. Signatera will be featured across 11 scientific abstracts, including 4 oral presentations. https://ow.ly/2L1E50Yn1O7 American Society of Clinical Oncology #GU26 #Natera

A positive readout from the SINERGY trial, a prospective Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma, was recently presented in an oral plenary session at the 2026 Multidisciplinary Head and Neck Cancers Symposium. #MHNCS26 Read more: https://ow.ly/gsZ350Ylky9

Hello from #SMFM26! Be sure to check out our symposium, presentations and connect with our team at booth #210! See details below 👇

We recently announced the launch of EDEN, a large, multi-center prospective study designed to evaluate Natera’s NIPT for early risk assessment of preeclampsia and other serious pregnancy complications. Read the full announcement: https://ow.ly/74IH50YccZf

We are proud to collaborate with Exelixis on the planned, phase III pivotal trial (STELLAR-316). It's another example of Natera's "Treat on Molecular Recurrence" approach, where patients will be treated with therapy if they test positive with Signatera™. Learn more: www.natera.com/company/news...

Our expanded 21-gene Fetal Focus™ single-gene non-invasive prenatal test is now available. https://ow.ly/rfUg50XSeWM

Together with Quantum Leap Healthcare Collaborative, we’re excited to share that new findings from the I-SPY 2 trial were published in Nature Communications. This publication shows Signatera™ can predict treatment response and recurrence risk in early-stage breast cancer. https://ow.ly/BYZR50XKpKV

Findings from RenaCARE, evaluating management of CKD one year after RenasightTM testing have been published in @asnpublications.bsky.social. Results show how genetic insights informed diagnosis, prognosis and family care decisions. https://ow.ly/cuze50XFUAH #CKD #Natera #Renasight

Personalized ctDNA testing for MRD is transforming adjuvant therapy decisions in muscle-invasive bladder cancer. Petros Grivas covers ctDNA's perioperative role, key trial data, and much more in this 30-min webinar. Watch now: www.emjreviews.com/en-us/amj/on... This content was funded by Natera.

Attending #SABCS25? Be sure to stop by booth 1309 to meet the Natera team and discuss our latest data. Below is our full list of presentations, showcasing Signatera™ as a leader in MRD testing across early and metastatic breast cancer. Learn more: https://ow.ly/iRP450XGmS5

Thank you to everyone who connected with us at #ASH25. We appreciated the opportunity to discuss emerging data and collaborate with colleagues. Learn more about the value Signatera™ can offer to lymphoma patients for personalized and precise care: www.natera.com/oncology/sig...